Assessment of Ki-67 and mitoses in pituitary neuroendocrine tumours—Consistency counts

IF 5.8 2区医学 Q1 CLINICAL NEUROLOGY

Brain Pathology Pub Date : 2024-07-15 DOI:10.1111/bpa.13285

Paul Benjamin Loughrey, Christine Greene, Kris D. McCombe, Fatima Abdullahi Sidi, Stephen McQuaid, Stephen Cooke, Steven J. Hunter, Brian Herron, Márta Korbonits, Stephanie G. Craig, Jacqueline A. James

引用次数: 0

Abstract

Pituitary neuroendocrine tumour Ki-67 proliferation index varies according to the number of tumour cells assessed. Consistent Ki-67 scoring approaches and re-evaluation of the recommended Ki-67 3% cut-off are required to clarify controversies in pituitary neuroendocrine tumour Ki-67 proliferation index assessment.

Abstract Image

查看原文本刊更多论文

垂体神经内分泌肿瘤中 Ki-67 和有丝分裂的评估--一致性计数。

垂体神经内分泌肿瘤的Ki-67增殖指数因评估的肿瘤细胞数量而异。为澄清垂体神经内分泌肿瘤 Ki-67 增殖指数评估中的争议，需要采用一致的 Ki-67 评分方法并重新评估推荐的 Ki-67 3% 临界值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brain Pathology 医学-病理学

CiteScore

13.20

自引率

3.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Brain Pathology is the journal of choice for biomedical scientists investigating diseases of the nervous system. The official journal of the International Society of Neuropathology, Brain Pathology is a peer-reviewed quarterly publication that includes original research, review articles and symposia focuses on the pathogenesis of neurological disease.